Our top pick for
DURECT Corporation is a drug manufacturers-specialty & generic business based in the US. DURECT Corporation shares (DRRX) are listed on the NASDAQ and all prices are listed in US Dollars. DURECT Corporation employs 81 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.52 - $2.96|
|50-day moving average||$1.94|
|200-day moving average||$2.04|
|Wall St. target price||$6.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.15|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$30.1 million|
|Gross profit TTM||$996,000|
|Return on assets TTM||-9.75%|
|Return on equity TTM||-45.53%|
|Market capitalisation||$429.7 million|
TTM: trailing 12 months
There are currently 9.5 million DURECT Corporation shares held short by investors – that's known as DURECT Corporation's "short interest". This figure is 3.7% up from 9.1 million last month.
There are a few different ways that this level of interest in shorting DURECT Corporation shares can be evaluated.
DURECT Corporation's "short interest ratio" (SIR) is the quantity of DURECT Corporation shares currently shorted divided by the average quantity of DURECT Corporation shares traded daily (recently around 1.1 million). DURECT Corporation's SIR currently stands at 8.39. In other words for every 100,000 DURECT Corporation shares traded daily on the market, roughly 8390 shares are currently held short.
However DURECT Corporation's short interest can also be evaluated against the total number of DURECT Corporation shares, or, against the total number of tradable DURECT Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DURECT Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DURECT Corporation shares in existence, roughly 40 shares are currently held short) or 0.0472% of the tradable shares (for every 100,000 tradable DURECT Corporation shares, roughly 47 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DURECT Corporation.
Find out more about how you can short DURECT Corporation stock.
We're not expecting DURECT Corporation to pay a dividend over the next 12 months.
Over the last 12 months, DURECT Corporation's shares have ranged in value from as little as $1.52 up to $2.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DURECT Corporation's is 1.4402. This would suggest that DURECT Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd. ; Santen Pharmaceutical Co.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.